| Several high-efficacy immune therapies can reduce the risk of disability progression in relapsing–remitting multiple sclerosis. |
| A standard definition of disability progression would facilitate comparative evaluation of therapies. |
| In relapsing multiple sclerosis, and potentially in certain progressive phenotypes, the best outcomes may be afforded by early treatment with the most effective immune therapies. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.